Cardiovascular effects of erythropoietin. An update

Anantha Vijay R Santhanam, Livius V. d'Uscio, Zvonimir S Katusic

Research output: Book/ReportBook

22 Citations (Scopus)

Abstract

Erythropoietin (EPO) is a therapeutic product of recombinant DNA technology and it has been in clinical use as stimulator of erythropoiesis over the last two decades. Identification of EPO and its receptor (EPOR) in the cardiovascular system expanded understanding of physiological and pathophysiological role of EPO. In experimental models of cardiovascular and cerebrovascular disorders, EPO exerts protection either by preventing apoptosis of cardiac myocytes, smooth muscle cells, and endothelial cells, or by increasing endothelial production of nitric oxide. In addition, EPO stimulates mobilization of progenitor cells from bone marrow thereby accelerating repair of injured endothelium and neovascularization. A novel signal transduction pathway involving EPOR-β-common heteroreceptor is postulated to enhance EPO-mediated tissue protection. A better understanding of the role of β-common receptor signaling as well as development of novel analogs of EPO with enhanced nonhematopoietic protective effects may expand clinical application of EPO in prevention and treatment of cardiovascular and cerebrovascular disorders.

Original languageEnglish (US)
PublisherUnknown Publisher
Number of pages28
Volume60
EditionC
DOIs
StatePublished - 2010

Publication series

NameAdvances in Pharmacology
No.C
Volume60
ISSN (Print)10543589

Fingerprint

Erythropoietin
Cerebrovascular Disorders
Erythropoietin Receptors
Recombinant DNA
Erythropoiesis
Cardiovascular System
Cardiac Myocytes
Smooth Muscle Myocytes
Endothelium
Signal Transduction
Nitric Oxide
Theoretical Models
Stem Cells
Endothelial Cells
Bone Marrow
Apoptosis
Technology

Keywords

  • Akt
  • Endothelium
  • ENOS
  • Erythropoietin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Santhanam, A. V. R., d'Uscio, L. V., & Katusic, Z. S. (2010). Cardiovascular effects of erythropoietin. An update. (C ed.) (Advances in Pharmacology; Vol. 60, No. C). Unknown Publisher. https://doi.org/10.1016/B978-0-12-385061-4.00009-X

Cardiovascular effects of erythropoietin. An update. / Santhanam, Anantha Vijay R; d'Uscio, Livius V.; Katusic, Zvonimir S.

C ed. Unknown Publisher, 2010. 28 p. (Advances in Pharmacology; Vol. 60, No. C).

Research output: Book/ReportBook

Santhanam, AVR, d'Uscio, LV & Katusic, ZS 2010, Cardiovascular effects of erythropoietin. An update. Advances in Pharmacology, no. C, vol. 60, vol. 60, C edn, Unknown Publisher. https://doi.org/10.1016/B978-0-12-385061-4.00009-X
Santhanam AVR, d'Uscio LV, Katusic ZS. Cardiovascular effects of erythropoietin. An update. C ed. Unknown Publisher, 2010. 28 p. (Advances in Pharmacology; C). https://doi.org/10.1016/B978-0-12-385061-4.00009-X
Santhanam, Anantha Vijay R ; d'Uscio, Livius V. ; Katusic, Zvonimir S. / Cardiovascular effects of erythropoietin. An update. C ed. Unknown Publisher, 2010. 28 p. (Advances in Pharmacology; C).
@book{f0ad16d83e76468c991f7b8ffe08dc47,
title = "Cardiovascular effects of erythropoietin. An update",
abstract = "Erythropoietin (EPO) is a therapeutic product of recombinant DNA technology and it has been in clinical use as stimulator of erythropoiesis over the last two decades. Identification of EPO and its receptor (EPOR) in the cardiovascular system expanded understanding of physiological and pathophysiological role of EPO. In experimental models of cardiovascular and cerebrovascular disorders, EPO exerts protection either by preventing apoptosis of cardiac myocytes, smooth muscle cells, and endothelial cells, or by increasing endothelial production of nitric oxide. In addition, EPO stimulates mobilization of progenitor cells from bone marrow thereby accelerating repair of injured endothelium and neovascularization. A novel signal transduction pathway involving EPOR-β-common heteroreceptor is postulated to enhance EPO-mediated tissue protection. A better understanding of the role of β-common receptor signaling as well as development of novel analogs of EPO with enhanced nonhematopoietic protective effects may expand clinical application of EPO in prevention and treatment of cardiovascular and cerebrovascular disorders.",
keywords = "Akt, Endothelium, ENOS, Erythropoietin",
author = "Santhanam, {Anantha Vijay R} and d'Uscio, {Livius V.} and Katusic, {Zvonimir S}",
year = "2010",
doi = "10.1016/B978-0-12-385061-4.00009-X",
language = "English (US)",
volume = "60",
series = "Advances in Pharmacology",
publisher = "Unknown Publisher",
number = "C",
edition = "C",

}

TY - BOOK

T1 - Cardiovascular effects of erythropoietin. An update

AU - Santhanam, Anantha Vijay R

AU - d'Uscio, Livius V.

AU - Katusic, Zvonimir S

PY - 2010

Y1 - 2010

N2 - Erythropoietin (EPO) is a therapeutic product of recombinant DNA technology and it has been in clinical use as stimulator of erythropoiesis over the last two decades. Identification of EPO and its receptor (EPOR) in the cardiovascular system expanded understanding of physiological and pathophysiological role of EPO. In experimental models of cardiovascular and cerebrovascular disorders, EPO exerts protection either by preventing apoptosis of cardiac myocytes, smooth muscle cells, and endothelial cells, or by increasing endothelial production of nitric oxide. In addition, EPO stimulates mobilization of progenitor cells from bone marrow thereby accelerating repair of injured endothelium and neovascularization. A novel signal transduction pathway involving EPOR-β-common heteroreceptor is postulated to enhance EPO-mediated tissue protection. A better understanding of the role of β-common receptor signaling as well as development of novel analogs of EPO with enhanced nonhematopoietic protective effects may expand clinical application of EPO in prevention and treatment of cardiovascular and cerebrovascular disorders.

AB - Erythropoietin (EPO) is a therapeutic product of recombinant DNA technology and it has been in clinical use as stimulator of erythropoiesis over the last two decades. Identification of EPO and its receptor (EPOR) in the cardiovascular system expanded understanding of physiological and pathophysiological role of EPO. In experimental models of cardiovascular and cerebrovascular disorders, EPO exerts protection either by preventing apoptosis of cardiac myocytes, smooth muscle cells, and endothelial cells, or by increasing endothelial production of nitric oxide. In addition, EPO stimulates mobilization of progenitor cells from bone marrow thereby accelerating repair of injured endothelium and neovascularization. A novel signal transduction pathway involving EPOR-β-common heteroreceptor is postulated to enhance EPO-mediated tissue protection. A better understanding of the role of β-common receptor signaling as well as development of novel analogs of EPO with enhanced nonhematopoietic protective effects may expand clinical application of EPO in prevention and treatment of cardiovascular and cerebrovascular disorders.

KW - Akt

KW - Endothelium

KW - ENOS

KW - Erythropoietin

UR - http://www.scopus.com/inward/record.url?scp=78349258535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349258535&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-385061-4.00009-X

DO - 10.1016/B978-0-12-385061-4.00009-X

M3 - Book

VL - 60

T3 - Advances in Pharmacology

BT - Cardiovascular effects of erythropoietin. An update

PB - Unknown Publisher

ER -